Opinion
To successfully compete against one another and Big Pharma for top talent, biotech companies need to do a better job of selling themselves.
While grappling with financial challenges, the biotech industry is forced to pivot to flexible business models.
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal.
A transformational moment in the treatment of depression, GSK takes first shot in a vaccine patent war with Pfizer, a Louisiana woman sues Novo Nordisk and Lilly, and companies face a steep COVID-19 cliff.
The industry may not have fully rebounded to the highs seen a couple of years ago, but there are sure signs of spring in the air.
A survey of 34 biotech websites reveals that the industry fails to provide quality information to help prospective job candidates understand why they should choose one company over another.
James Ellis, an authority on employer branding for small businesses and biotechs, weighs in on the best ways to earn candidates’ trust.
Bringing new drugs to the market costs billions of dollars. It could not be done without investments by both the NIH and biopharma companies.
The youngest generation to enter the workforce has mastered working to live, not living to work. Adopting this mindset made me not only more fulfilled, but more successful in my career.